Early Multicenter Experience With Imipenem-Cilastatin-Relebactam for Multidrug-Resistant Gram-Negative Infections

Authors

Nicholas Rebold, Wayne State University
Taylor Morrisette, Wayne State University
Abdalhamid M. Lagnf, Wayne State University
Sara Alosaimy, Wayne State University

Document Type

Article

Publication Date

12-1-2021

Abstract

A multicenter case series of 21 patients were treated with imipenem-cilastatin-relebactam. There were mixed infection sources, with pulmonary infections (11/21,52%) composing the majority. The primary pathogen was Pseudomonas aeruginosa (16/21, 76%), and 15/16 (94%) isolates were multidrug-resistant. Thirty-day survival occurred in 14/21 (67%) patients. Two patients experienced adverse effects.

Relational Format

journal article

Recommended Citation

Rebold, N., Morrisette, T., Lagnf, A. M., Alosaimy, S., Holger, D., Barber, K., Justo, J. A., Antosz, K., Carlson, T. J., Frens, J. J., Biagi, M., Kufel, W. D., Moore, W. J., Mercuro, N., Raux, B. R., & Rybak, M. J. (2021). Early multicenter experience with imipenem-cilastatin-relebactam for multidrug-resistant gram-negative infections. Open Forum Infectious Diseases, 8(12), ofab554. https://doi.org/10.1093/ofid/ofab554

DOI

10.1093/ofid/ofab554

Accessibility Status

Searchable text